Brokerages Set Niagen Bioscience, Inc. (NASDAQ:NAGE) Price Target at $13.42

Shares of Niagen Bioscience, Inc. (NASDAQ:NAGE) have earned an average recommendation of “Moderate Buy” from the six brokerages that are presently covering the company, Marketbeat reports. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company. The average 1-year price target among brokerages that have updated their coverage on the stock in the last year is $13.42.

A number of brokerages recently issued reports on NAGE. Canaccord Genuity Group increased their price objective on Niagen Bioscience from $13.00 to $16.00 and gave the stock a “buy” rating in a report on Tuesday, June 10th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Niagen Bioscience in a research note on Saturday, September 27th. Roth Capital reaffirmed a “buy” rating and set a $23.00 price target (up from $10.00) on shares of Niagen Bioscience in a research note on Friday, June 6th. HC Wainwright increased their price target on Niagen Bioscience from $11.00 to $12.00 and gave the company a “buy” rating in a research note on Monday, August 11th. Finally, Wall Street Zen lowered Niagen Bioscience from a “strong-buy” rating to a “buy” rating in a research note on Tuesday, September 9th.

Niagen Bioscience Price Performance

Shares of NAGE stock opened at $6.93 on Friday. Niagen Bioscience has a 12-month low of $3.18 and a 12-month high of $14.69. The firm has a market capitalization of $552.67 million, a price-to-earnings ratio of 33.00 and a beta of 2.13. The business has a 50 day simple moving average of $9.57 and a 200 day simple moving average of $9.48.

Niagen Bioscience (NASDAQ:NAGE) last issued its quarterly earnings data on Wednesday, August 6th. The company reported $0.04 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $0.02 by $0.02. Niagen Bioscience had a return on equity of 23.12% and a net margin of 15.24%.The business had revenue of $31.12 million during the quarter, compared to analyst estimates of $28.55 million.

Hedge Funds Weigh In On Niagen Bioscience

Institutional investors and hedge funds have recently added to or reduced their stakes in the company. State of Wyoming bought a new position in Niagen Bioscience during the 4th quarter valued at $39,000. ProShare Advisors LLC bought a new stake in shares of Niagen Bioscience during the 4th quarter worth $74,000. Deutsche Bank AG boosted its stake in shares of Niagen Bioscience by 1,733.4% during the 4th quarter. Deutsche Bank AG now owns 26,878 shares of the company’s stock worth $143,000 after acquiring an additional 25,412 shares in the last quarter. Bank of America Corp DE boosted its stake in shares of Niagen Bioscience by 89.5% during the 4th quarter. Bank of America Corp DE now owns 52,144 shares of the company’s stock worth $277,000 after acquiring an additional 24,622 shares in the last quarter. Finally, Squarepoint Ops LLC bought a new stake in shares of Niagen Bioscience during the 4th quarter worth $555,000. 15.41% of the stock is owned by institutional investors.

About Niagen Bioscience

Niagen Bioscience, Inc is a global bioscience company, which engages in acquiring, developing, and commercializing proprietary-based ingredient technologies. It is pioneering research on nicotinamide adenine dinucleotide (NAD+). The company’s patent portfolio includes Nicotinamide Riboside (NR) and other NAD+ precursors, which are commercialized as the flagship ingredient Niagen.